Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme J Moyle

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Current HIV/AIDS Reports|August 11, 2005
Plastic surgical approaches for HIV-associated lipoatrophyGraeme J Moyle
Current Opinion in Infectious Diseases|April 20, 2002
Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infectionGraeme J. Moyle
The AIDS Reader|November 4, 2005
Editorial comment: boosted PIs and metabolism--it's not just the ritonavirGraeme J Moyle
The AIDS Reader|February 17, 2005
The impact of abacavir on lipids and lipodystrophyGraeme J Moyle
The AIDS Reader|December 3, 2003
Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backboneGraeme J Moyle
The AIDS Reader|July 31, 2004
Simplifying suppression: switching therapies to improve HIV disease managementGraeme J Moyle
The AIDS Reader|August 29, 2006
Bone mineral abnormalities in persons with HIV infection: signal or noise?Kasha Singh, Graeme J Moyle
The AIDS Reader|June 17, 2004
Can we boost enough without ritonavir?Marta Boffito, Graeme J Moyle
The AIDS Reader|April 8, 2004
Pharmacokinetic considerations for combining 2 protease inhibitorsMarta Boffito, Graeme J Moyle
AIDS (London, England)|April 16, 2002
Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysisGraeme J Moyle, Brian G Gazzard
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Current HIV/AIDS Reports|August 11, 2005
Plastic surgical approaches for HIV-associated lipoatrophyGraeme J Moyle
Current Opinion in Infectious Diseases|April 20, 2002
Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infectionGraeme J. Moyle
The AIDS Reader|November 4, 2005
Editorial comment: boosted PIs and metabolism--it's not just the ritonavirGraeme J Moyle
The AIDS Reader|February 17, 2005
The impact of abacavir on lipids and lipodystrophyGraeme J Moyle
The AIDS Reader|December 3, 2003
Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backboneGraeme J Moyle
The AIDS Reader|July 31, 2004
Simplifying suppression: switching therapies to improve HIV disease managementGraeme J Moyle
The AIDS Reader|August 29, 2006
Bone mineral abnormalities in persons with HIV infection: signal or noise?Kasha Singh, Graeme J Moyle
The AIDS Reader|June 17, 2004
Can we boost enough without ritonavir?Marta Boffito, Graeme J Moyle
The AIDS Reader|April 8, 2004
Pharmacokinetic considerations for combining 2 protease inhibitorsMarta Boffito, Graeme J Moyle
AIDS (London, England)|April 16, 2002
Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysisGraeme J Moyle, Brian G Gazzard
Pageof 6